Clinical trial
Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar
NCT00174226 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00174226 |
|---|---|
| Title | Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar |
| Official title | Eight-Week, Double-Blind, 3-Arm Parallel, Placebo-Controlled, Randomized Efficacy And Safety Trial Of Atomoxetine, Atomoxetine Plus Buspirone, And Placebo In Adults With Attention Deficit Hyperactivity Disorder |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Attention Deficit Disorder With Hyperactivity |
| Intervention type | Drug |
| Interventions | Atomoxetine, Buspirone |
| Enrollment | 241 |
| Start date | Nov 1, 2004 |
| Completion | Jan 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Jul 15, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: